$CDLX
Cardlytics, Inc. Stock $cdlx

$cdlx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000166607124000094 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$69.64M	$67.61M
YoY Change	-9.21%	5.09%
Cost Of Revenue	$33.26M	$30.54M
YoY Change	-15.09%	-8.51%
Gross Profit	$36.38M	$37.07M
YoY Change	-3.07%	19.77%
Gross Profit Margin	52.24%	54.82%
Selling, General & Admin	$30.18M	$28.60M
YoY Change	-21.61%	5.87%
% of Gross Profit	82.95%	77.17%
Research & Development	$13.47M	$13.05M
YoY Change	-9.27%	12.83%
% of Gross Profit	37.03%	35.2%
Depreciation & Amortization	$6.529M	$6.250M
YoY Change	-9.32%	-4.94%
% of Gross Profit	17.95%	16.86%
Operating Expenses	$43.65M	$41.65M
YoY Change	-39.21%	7.95%
Operating Profit	-$15.81M	-$22.83M
YoY Change	-53.86%	-286.69%
Interest Expense	-$1.462M	-$1.449M
YoY Change	-279.39%	-204.92%
% of Operating Profit
Other Income/Expense, Net	$11.56M	-$1.449M
YoY Change	1317.79%	-204.92%
Pretax Income	-$4.257M	-$24.28M
YoY Change	-81.89%	-278.39%
Income Tax
% Of Pretax Income
Net Earnings	-$4.257M	-$24.28M
YoY Change	-81.89%	-278.39%
Net Earnings / Revenue	-6.11%	-35.91%
Basic Earnings Per Share	-$0.09	-$0.56
Diluted Earnings Per Share	-$0.09	-$0.56
COMMON SHARES
Basic Shares Outstanding	48.78M shares	44.11M shares
Diluted Shares Outstanding	49.06M shares	43.25M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.25M	$97.77M
YoY Change	-22.61%	-29.76%
Cash & Equivalents	$71.25M	$97.77M
Short-Term Investments
Other Short-Term Assets	$6.717M	$9.491M
YoY Change	-14.97%	13.76%
Inventory
Prepaid Expenses
Receivables	$102.7M	$105.2M
Other Receivables	$4.696M	$5.834M
Total Short-Term Assets	$185.3M	$218.3M
YoY Change	-8.12%	-11.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.084M	$2.906M
YoY Change	-61.02%	-38.89%
Goodwill	$277.2M	$277.2M
YoY Change	-21.41%	-21.41%
Intangibles	$29.43M	$32.22M
YoY Change	-36.79%	-35.57%
Long-Term Investments
YoY Change
Other Assets	$2.290M	$3.023M
YoY Change	-8.14%	15.34%
Total Long-Term Assets	$349.0M	$350.7M
YoY Change	-19.13%	-19.97%
TOTAL ASSETS
Total Short-Term Assets	$185.3M	$218.3M
Total Long-Term Assets	$349.0M	$350.7M
Total Assets	$534.4M	$569.0M
YoY Change	-15.62%	-16.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.866M	$3.974M
YoY Change	186.57%	91.7%
Accrued Expenses	$6.772M	$4.317M
YoY Change	-69.27%	-80.37%
Deferred Revenue	$1.679M	$1.994M
YoY Change	-44.31%	-27.99%
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$7.000K	$9.000K
YoY Change	-81.08%
Total Short-Term Liabilities	$104.6M	$102.6M
YoY Change	-37.71%	-46.26%
LONG-TERM LIABILITIES
Long-Term Debt	$212.9M	$257.9M
YoY Change	-6.12%	0.58%
Other Long-Term Liabilities	$17.00K	$9.370M
YoY Change	-99.32%	86.43%
Total Long-Term Liabilities	$17.00K	$267.3M
YoY Change	-99.99%	2.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.6M	$102.6M
Total Long-Term Liabilities	$17.00K	$267.3M
Total Liabilities	$324.3M	$369.8M
YoY Change	-18.35%	-18.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.140B	-$1.136B
YoY Change	15.54%	17.92%
Common Stock	$1.347B	$1.332B
YoY Change	10.44%	11.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$210.0M	$199.1M
YoY Change
Total Liabilities & Shareholders Equity	$534.4M	$569.0M
YoY Change	-15.62%	-16.89%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$4.257M	-$24.28M
YoY Change	-81.89%	-278.39%
Depreciation, Depletion And Amortization	$6.529M	$6.250M
YoY Change	-9.32%	-4.94%
Cash From Operating Activities	$4.429M	-$17.62M
YoY Change	-22.99%	75.05%
INVESTING ACTIVITIES
Capital Expenditures	$4.858M	$651.0K
YoY Change	76.85%	80.83%
Acquisitions
YoY Change
Other Investing Activities	$202.0K
YoY Change
Cash From Investing Activities	-$4.656M	-$4.747M
YoY Change	69.49%	69.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-26.29M	$28.32M
YoY Change	-47.51%	-5.54%
NET CHANGE
Cash From Operating Activities	4.429M	-$17.62M
Cash From Investing Activities	-4.656M	-$4.747M
Cash From Financing Activities	-26.29M	$28.32M
Net Change In Cash	-26.51M	$5.936M
YoY Change	-43.67%	-65.67%
FREE CASH FLOW
Cash From Operating Activities	$4.429M	-$17.62M
Capital Expenditures	$4.858M	$651.0K
Free Cash Flow	-$429.0K	-$18.27M
YoY Change	-114.28%	75.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Liabilities Liabilities	439346000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14118000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13948000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13048000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11564000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	369814000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48174000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48174000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39728000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39728000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1331628000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1243594000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3047000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2467000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1135547000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1111272000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	199137000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	134798000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	568951000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	574144000	usd
CY2024Q1	us-gaap	Revenues Revenues	67608000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2024Q1	cdlx	Financial Institution Share And Other Third Party Costs FinancialInstitutionShareAndOtherThirdPartyCosts	30543000	usd
CY2023Q1	cdlx	Financial Institution Share And Other Third Party Costs FinancialInstitutionShareAndOtherThirdPartyCosts	33384000	usd
CY2024Q1	cdlx	Delivery Costs DeliveryCosts	6173000	usd
CY2023Q1	cdlx	Delivery Costs DeliveryCosts	6424000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14485000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070000	usd
CY2024Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	0	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1723000	usd
CY2024Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	5817000	usd
CY2023Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-34584000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6250000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6575000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	90434000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	52104000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22826000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12227000	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-819000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-8000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-630000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1389000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1449000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1381000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24275000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13608000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24275000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43248000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33595000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43248000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36727000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-24275000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	580000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1274000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23695000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12334000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	134798000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12256000	usd
CY2024Q1	cdlx	Stock Issued During Period Shares Settlement Agreement StockIssuedDuringPeriodSharesSettlementAgreement	3592000	shares
CY2024Q1	cdlx	Stock Issued During Period Values Settlement Agreement StockIssuedDuringPeriodValuesSettlementAgreement	27451000	usd
CY2024Q1	cdlx	Stock Issued During Period Values Settlement Agreement StockIssuedDuringPeriodValuesSettlementAgreement	27451000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3908000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48322000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48322000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	580000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	199137000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	211605000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8381000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1274000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	232320000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1570000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-246000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6250000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6575000	usd
CY2024Q1	cdlx	Capitalized Contract Cost Amortization Interest Expense CapitalizedContractCostAmortizationInterestExpense	445000	usd
CY2023Q1	cdlx	Capitalized Contract Cost Amortization Interest Expense CapitalizedContractCostAmortizationInterestExpense	407000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	549000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1235000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10985000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7968000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5817000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-34584000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-667000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	905000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13323000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-21405000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3450000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	369000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	125000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1691000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7634000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3136000	usd
CY2024Q1	cdlx	Increase Decrease In Financial Institution Share Liability IncreaseDecreaseInFinancialInstitutionShareLiability	-13291000	usd
CY2023Q1	cdlx	Increase Decrease In Financial Institution Share Liability IncreaseDecreaseInFinancialInstitutionShareLiability	-9701000	usd
CY2024Q1	cdlx	Increase Decrease In Consumer Incentive Liability IncreaseDecreaseInConsumerIncentiveLiability	-8698000	usd
CY2023Q1	cdlx	Increase Decrease In Consumer Incentive Liability IncreaseDecreaseInConsumerIncentiveLiability	-10630000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17617000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10064000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	651000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	360000	usd
CY2024Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	4096000	usd
CY2023Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	2442000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4747000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2802000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	30000000	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	20074000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48634000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	239000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	15000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28321000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29981000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5936000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17291000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91830000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121985000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97766000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139276000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97766000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139194000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	82000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97766000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139276000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1862000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1268000	usd
CY2024Q1	cdlx	Property And Equipment Incurred But Not Yet Paid PropertyAndEquipmentIncurredButNotYetPaid	98000	usd
CY2023Q1	cdlx	Property And Equipment Incurred But Not Yet Paid PropertyAndEquipmentIncurredButNotYetPaid	0	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	135000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024Q1	cdlx	Noncash Or Part Noncash Acquisition Accrued Consideration NoncashOrPartNoncashAcquisitionAccruedConsideration	27451000	usd
CY2023Q1	cdlx	Noncash Or Part Noncash Acquisition Accrued Consideration NoncashOrPartNoncashAcquisitionAccruedConsideration	0	usd
CY2021Q2	cdlx	Contingent Consideration Number Of Earnout Payments ContingentConsiderationNumberOfEarnoutPayments	2	payment
CY2023Q4	cdlx	First Anniversary Annualized Recurring Revenue Cash Paid FirstAnniversaryAnnualizedRecurringRevenueCashPaid	50100000	usd
CY2023Q4	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	2740418	shares
CY2024Q1	cdlx	Settlement Agreement Annualized Recurring Revenue Cash Paid SettlementAgreementAnnualizedRecurringRevenueCashPaid	25000000	usd
CY2024Q1	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	3600000	shares
CY2024Q1	cdlx	Settlement Agreement Annualized Recurring Revenue Cash Paid SettlementAgreementAnnualizedRecurringRevenueCashPaid	20000000	usd
CY2024Q1	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	3600000	shares
CY2024Q1	cdlx	Business Acquisition Number Of Tranches BusinessAcquisitionNumberOfTranches	2	tranche
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements. Significant items subject to such estimates and assumptions include revenue recognition, internal-use software development costs, stock-based compensation, allowance for doubtful accounts, valuation of acquired intangible assets of Bridg, valuation of contingent consideration for Bridg, valuation of long-lived assets, goodwill valuation, income tax including valuation allowance and contingencies. We base our estimates on historical experience and on assumptions that we believe are reasonable. Changes in facts or circumstances may cause us to change our assumptions and estimates in future periods and it is possible that actual results could differ from our current or revised future estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic Considerations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unfavorable conditions in the economy both in the United States and abroad may negatively affect the growth of our business and our results of operations. For example, macroeconomic events, including the changes in inflation, the U.S. Federal Reserve raising interest rates, disruptions in access to bank deposits or lending commitments due to bank failures, the Russia-Ukraine war and the Middle East conflict have led to economic uncertainty globally. Historically, during periods of economic uncertainty and downturns, businesses may slow spending on advertising, which may impact our business and our customers’ businesses.</span></div>The effect of macroeconomic conditions may not be fully reflected in our results of operations until future periods. If, however, economic uncertainty increases or the global economy worsens, our business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition and operating results, see the section titled "Risk Factors.
CY2024Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	0	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1700000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	277202000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	89985000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	57841000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32144000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	92300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	52424000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	34929000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2800000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3500000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	8338000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	11117000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9674000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3015000	usd
CY2024Q1	cdlx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32144000	usd
CY2024Q1	cdlx	Consumer Incentives Expense ConsumerIncentivesExpense	37600000	usd
CY2023Q1	cdlx	Consumer Incentives Expense ConsumerIncentivesExpense	31300000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62233000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59030000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	66000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	41000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2044000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2271000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	35800000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	12100000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8342000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7310000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	14000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8347000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7324000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2079000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2127000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7652000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6391000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	9000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10000	usd
CY2024Q1	cdlx	Lease Liability LeaseLiability	9740000	usd
CY2023Q4	cdlx	Lease Liability LeaseLiability	8528000	usd
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	227870000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	227504000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	257870000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	257504000	usd
CY2024Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	100000	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	900000	usd
CY2020Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	230000000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2020Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	222700000	usd
CY2020Q3	cdlx	Adjustments To Additional Paid In Capital Issuance Of Capped Calls AdjustmentsToAdditionalPaidInCapitalIssuanceOfCappedCalls	26500000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2020Q3	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	10000	numberofdays
CY2020Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.98
CY2020Q3	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	11.7457
CY2020Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	85140
CY2020Q3	cdlx	Debt Instrument Convertible Redemption Period Days Before Maturity Date DebtInstrumentConvertibleRedemptionPeriodDaysBeforeMaturityDate	P36D
CY2020Q3	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1
CY2024Q1	cdlx	Debt Instrument Convertible Threshold Principal Outstanding Amount For Partial Redemption DebtInstrumentConvertibleThresholdPrincipalOutstandingAmountForPartialRedemption	75000000	usd
CY2020Q3	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1
CY2024Q1	cdlx	Debt Instrument Convertible Liability Component Discount Rate DebtInstrumentConvertibleLiabilityComponentDiscountRate	0.0650
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	575000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	575000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	365000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	365000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	940000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	940000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0164
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0164
CY2020Q3	cdlx	Adjustments To Additional Paid In Capital Issuance Of Capped Calls AdjustmentsToAdditionalPaidInCapitalIssuanceOfCappedCalls	26500000	usd
CY2020Q3	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	85.14
CY2020Q3	cdlx	Option Indexed To Issuers Equity Cap Price OptionIndexedToIssuersEquityCapPrice	128.51
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2024Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	29500000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	961558	shares
CY2024Q1	cdlx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Annual Percentage Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease	0.05
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1986417	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10985000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7968000	usd
CY2024Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1300000	usd
CY2023Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	400000	usd
CY2023Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	43560000	usd
CY2022Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	104121000	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	-45114000	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Affiliates Current IncreaseDecreaseInDueToAffiliatesCurrent	0	usd
CY2024Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	5817000	usd
CY2023Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-34584000	usd
CY2024Q1	us-gaap	Accelerated Share Repurchases Settlement Payment Or Receipt AcceleratedShareRepurchasesSettlementPaymentOrReceipt	-4263000	usd
CY2023Q1	us-gaap	Accelerated Share Repurchases Settlement Payment Or Receipt AcceleratedShareRepurchasesSettlementPaymentOrReceipt	0	usd
CY2024Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	0	usd
CY2023Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	69537000	usd
CY2023Q4	cdlx	First Anniversary Annualized Recurring Revenue Cash Paid FirstAnniversaryAnnualizedRecurringRevenueCashPaid	50100000	usd
CY2023Q4	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	2740418	shares
CY2024Q1	cdlx	Settlement Agreement Annualized Recurring Revenue Cash Paid SettlementAgreementAnnualizedRecurringRevenueCashPaid	25000000	usd
CY2024Q1	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	3600000	shares
CY2024Q1	cdlx	Settlement Agreement Annualized Recurring Revenue Cash Paid SettlementAgreementAnnualizedRecurringRevenueCashPaid	20000000	usd
CY2024Q1	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	3600000	shares
CY2024Q1	us-gaap	Significant Supply Commitment Remaining Minimum Amount Committed SignificantSupplyCommitmentRemainingMinimumAmountCommitted	4500000	usd
CY2024Q1	us-gaap	Payments To Suppliers PaymentsToSuppliers	2400000	usd
CY2023Q1	us-gaap	Significant Supply Commitment Remaining Minimum Amount Committed SignificantSupplyCommitmentRemainingMinimumAmountCommitted	1300000	usd
CY2023Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	13500000	usd
CY2024Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	17000000	usd
CY2020Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	230000000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2023Q2	cdlx	First Anniversary Annualized Recurring Revenue FirstAnniversaryAnnualizedRecurringRevenue	23200000	usd
CY2024Q1	cdlx	First Anniversary Annualized Recurring Revenue Cash Paid FirstAnniversaryAnnualizedRecurringRevenueCashPaid	25000000	usd
CY2024Q1	cdlx	Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Delivered BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesDelivered	3600000	shares
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24275000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	13608000	usd
CY2024Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	usd
CY2023Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	940000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24275000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14548000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43248000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33595000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2701000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43248000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36727000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2024Q1	us-gaap	Revenues Revenues	67608000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2024Q1	cdlx	Financial Institution Share And Oth0er Third Party Costs Excluding Non Cash Equity Expense And Deferred Implementation Costs FinancialInstitutionShareAndOth0erThirdPartyCostsExcludingNonCashEquityExpenseAndDeferredImplementationCosts	30543000	usd
CY2023Q1	cdlx	Financial Institution Share And Oth0er Third Party Costs Excluding Non Cash Equity Expense And Deferred Implementation Costs FinancialInstitutionShareAndOth0erThirdPartyCostsExcludingNonCashEquityExpenseAndDeferredImplementationCosts	33384000	usd
CY2024Q1	cdlx	Adjusted Contribution AdjustedContribution	37065000	usd
CY2023Q1	cdlx	Adjusted Contribution AdjustedContribution	30947000	usd
CY2024Q1	cdlx	Adjusted Contribution AdjustedContribution	37065000	usd
CY2023Q1	cdlx	Adjusted Contribution AdjustedContribution	30947000	usd
CY2024Q1	cdlx	Delivery Costs DeliveryCosts	6173000	usd
CY2023Q1	cdlx	Delivery Costs DeliveryCosts	6424000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14118000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13948000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13048000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11564000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14485000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070000	usd
CY2024Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	0	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1723000	usd
CY2024Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	5817000	usd
CY2023Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-34584000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6250000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6575000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1449000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1381000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24275000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13608000	usd
CY2024Q1	us-gaap	Revenues Revenues	67608000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2906000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3323000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001666071-24-000094-index-headers.html	Edgar Link	pending
0001666071-24-000094-index.html	Edgar Link	pending
0001666071-24-000094.txt	Edgar Link	pending
0001666071-24-000094-xbrl.zip	Edgar Link	pending
cdlx-20240331.htm	Edgar Link	pending
cdlx-20240331.xsd	Edgar Link	pending
cdlx-20240331_g1.jpg	Edgar Link	pending
cdlx_form10-qx2024q1xex103.htm	Edgar Link	pending
cdlx_form10-qx2024q1xex104.htm	Edgar Link	pending
cdlx_form10-qx2024q1xex311.htm	Edgar Link	pending
cdlx_form10-qx2024q1xex312.htm	Edgar Link	pending
cdlx_form10-qx2024q1xex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
cdlx-20240331_cal.xml	Edgar Link	unprocessable
cdlx-20240331_lab.xml	Edgar Link	unprocessable
cdlx-20240331_def.xml	Edgar Link	unprocessable
cdlx-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdlx-20240331_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDLX
Cardlytics, Inc. Stock $cdlx

2024 Q2 Form 10-Q Financial Statement

#000166607124000094 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDLX Cardlytics, Inc. Stock $cdlx

2024 Q2 Form 10-Q Financial Statement

#000166607124000094 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDLX
Cardlytics, Inc. Stock $cdlx